A lipid-anchored neurokinin 1 receptor antagonist prolongs pain relief by a three-pronged mechanism of action targeting the receptor at the plasma membrane and in endosomes

HIGHLIGHTS

• who: Quynh N. Mai from the Quynh NMai1, , Priyank Shenoy1, Tim Quach2, Jeffri S. Retamal2, Arisbel B. Gondin1, Holly R. Yeatman1, Luigi Aurelio1, Joshua W. Conner3, Daniel P. Poole1, Meritxell Canals5, Cameron J. Nowell1, Bim Graham4, Thomas P. Davis2, , Stephen J. Briddon5, Stephen J. Hill5, Christopher J. H. Porter2, Nigel W. Bunnett1, , *, Michelle L. Halls1, *, and Nicholas A. Veldhuis1, , * From the Drug Discovery Biology Theme, Drug Delivery, Disposition and Dynamics Theme, Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, and Medicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.